NCT04074135 2026-04-20
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
21 trialsNCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04924075 2026-04-13
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT00102544 2026-04-08
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
National Institutes of Health Clinical Center (CC)
Phase NA Enrolling by invitation
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT03401788 2024-12-03
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT03108066 2024-09-24
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT06553339 2024-08-14
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT00330564 2024-06-27
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05424016 2023-12-13
PRO-HEB
Assistance Publique - Hôpitaux de Paris
Phase NA Recruiting
NCT05843305 2023-05-06
A Study of BPI-452080 in Subjects With Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT03001349 2021-02-15
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01967537 2019-11-19
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02108002 2018-09-14
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00089765 2017-07-02
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00052013 2017-03-06
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
Phase 2 Completed
NCT01266070 2017-02-13
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00088374 2012-07-27
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01015300 2012-05-11
Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Terminated
NCT00056199 2008-03-04
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed